Altus Pharmaceuticals, Inc. has entered into an agreement with Genentech to develop, manufacture and commercialize ALTU-238, Altus’ subcutaneous formulation of human growth hormone (HGH), which employs Altus’ protein crystallization and formulation technology, for patients with growth hormone deficiencies. The alliance and license agreement is exclusive to North America with an option for a global agreement. Genentech will make a $15 million upfront payment to Altus with the pot...